RADIOACTIVE CEMENT OF PMMA AND HAP-Sm-153, Ho-166, OR RE-188 FOR BONE METASTASIS TREATMENT

Montaño, Carlos Julio; Campos, Tânia Maria Mendonça

doi:10.1590/1413-785220192701190288

Cited by 6 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, due to the deep penetration of the photons emitted from the seeds, sparing of the radiosensitive nearby tissues, i.e., SC and nerve roots need more attention. It is not serious for beta-emitting bone cement since the dose rapidly drops off up to 3 mm from the cement surface [ 12 , 22 ]. Therefore, the employment of beta-emitting bone cement is more interesting for situations in which the tumor is near the spinal canal due to its steep dose gradient.…”

Section: Discussionmentioning

confidence: 99%

Monte Carlo Dosimetric Study of Percutaneous Vertebroplasty and Brachytherapy for the Treatment of Spinal Metastases

2023

J Biomed Phys Eng

View full text Add to dashboard Cite

Background: Percutaneous vertebroplasty employs bone cement for injecting into the fractured vertebral body (VB) caused by spinal metastases. Radioactive bone cement and also brachytherapy seeds have been utilized to suppress the tumor growth in the VB. Objective: This study aims to investigate the dose distributions of low-energy brachytherapy seeds, and to compare them to those of radioactive bone cement, by Monte Carlo simulation. Material and Methods: In this simulation study, nine CT scan images were imported in Geant4. For the simulation of brachytherapy, I-125, Cs-131, or Pd-103 seeds were positioned in the VB, and for the simulation of vertebroplasty, the VB was filled by a radioactive cement loaded by P-32, Ho-166, Y-90, or Sm-153 radioisotopes. The dose-volume histograms of the VB, and the spinal cord (SC) were obtained after segmentation, considering that the reference dose is the minimum dose covered 95% of the VB. Results: The SC sparing was improved by using beta-emitting cement because of their steep gradient dose distribution. I-125 seeds and Y-90 radioisotope showed better VB coverage for brachytherapy and vertebroplasty techniques, respectively. Pd-103 seeds and P-32 radioisotope showed better SC sparing for brachytherapy and vertebroplasty, respectively. The minimum mean doses that covered 100% of the VB were 62.0%, 56.5%, and 45.0% for I-125, Cs-131, and Pd-103 seeds, and 28.3%, 28.6%, 32.9%, and 17.7%, for P-32, Ho-166, Y-90, and Sm-153 sources, respectively. Conclusion: I-125 and Cs-131 seeds may be useful for large tumors filling the entire VB, and also for the extended tumors invading multiple vertebrae. Beta-emitting bone cement is recommended for tumors located near the SC.

show abstract

Section: Discussionmentioning

confidence: 99%

Monte Carlo Dosimetric Study of Percutaneous Vertebroplasty and Brachytherapy for the Treatment of Spinal Metastases

2023

J Biomed Phys Eng

View full text Add to dashboard Cite

show abstract

“…However, as with other approaches to radioactive bone cement (Tan et al 2020 ; Hirsch et al 2008 ), further clinical research and data must be collected before this relatively novel approach to spinal cancer and metastasis treatment is deemed appropriate for widespread clinical application. A similar approach was employed in another study with polymethylmethacrylate (PMMA) and hydroxyapatite (HA) as the bone cement, with results being similarly promising, however it was noted that further study regarding radiotoxicity, cytotoxicity, dosimetry, radiobiology and performance in the clinic must be conducted for further progress to be made (Montaño and Campos 2019 ).…”

Section: Samarium: 153 Smmentioning

confidence: 99%

“…In light of these results, more investigation into specific dosimetry requirements, in vivo studies of pharmacokinetics, biodistribution and stability are needed for progress to be made in this regard (Tan et al 2020). Moreover, the potential for 153 Sm to be incorporated into treatment for spinal cancer and metastases has been explored (Donanzam et al 2013;Montaño and Campos 2019). Added advantages such as cost-effectiveness, ease of production, theranostic properties and availability have led 153 Sm to be regarded as a potential radionuclide for these applications, with the most useful characteristic being its ability to be imaged as well as provide the appropriate β − -therapy.…”

Section: Samarium: 153 Smmentioning

confidence: 99%

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.

show abstract

“…Bremsstrahlung imaging can trace the tumor sites in the human body. Iodine ( 131 I) is used in thyroid cancer therapy and samarium ( 153 Sm) in osseous metastases therapy [25,26]. In bremsstrahlung radiation therapy [27], the released beta particles interact with body organs such as bone and muscles resulting in the production of EB spectrum with different energies and intensities.…”

Section: Introduction mentioning

confidence: 99%

External Bremsstrahlung Studies on Films of Lead Monoxide Filled Polycarbonate Composite

Kandagal,

Lobo

2023

Atom Indo.

View full text Add to dashboard Cite

The development of high-Z (high atomic number) radiation shielding materials is vital in order to protect personnel who work with harmful gamma radiation sources. At the same time, the emission of external bremsstrahlung (EB) radiation in those shielding materials when the radiation source emits beta particles as well as gamma radiation is also of prime concern.The production of EB in films of lead monoxide (PbO) loaded polycarbonate (PC) composite at eleven different filler levels (FLs) varying, in terms of weight fraction, from 0.0 % up to 10.0 % were investigated experimentally by using beta particles from strontium-90/yttrium-90 (90Sr/90Y) radioactive source. A nonlinear relation is observed between EB intensity and target thickness. The effective atomic numbers of the prepared PbO-filled PC composite films (at different FLs) were determined via EB measurements, followed by calculations, and the values obtained were compared with the modified atomic numbers which were determined for the same composite films (at different FLs) using the Markowicz and Van Grieken equation, and it was found that they are in good agreement. Finally, the atomic number dependence of EB in these composite films (PbO-filled PC composites) has been studied. It is obtained that the intensity of EB spectra depends on the square of the atomic number of the target material.

show abstract

RADIOACTIVE CEMENT OF PMMA AND HAP-Sm-153, Ho-166, OR RE-188 FOR BONE METASTASIS TREATMENT

Cited by 6 publications

References 21 publications

Monte Carlo Dosimetric Study of Percutaneous Vertebroplasty and Brachytherapy for the Treatment of Spinal Metastases

Monte Carlo Dosimetric Study of Percutaneous Vertebroplasty and Brachytherapy for the Treatment of Spinal Metastases

Cutting edge rare earth radiometals: prospects for cancer theranostics

External Bremsstrahlung Studies on Films of Lead Monoxide Filled Polycarbonate Composite

Contact Info

Product

Resources

About